“A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis”, J of Skin, vol. 1, no. 3.1, p. s29, Oct. 2017, doi: 10.25251/skin.1.supp.28.